Author

A. Dodson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 10

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 10 Organism:non-human primate· 8 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Research Focus:benchmarking· 2 Organism:rat· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Cook· 9 shared L. Pessaint· 9 shared M. Gagne· 9 shared S. F. Andrew· 8 shared D. R. Flebbe· 7 shared J.-P. M. Todd· 7 shared K. E. Foulds· 7 shared A. Van Ry· 6 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

A. Cook

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

M. Gagne, B. J. Flynn, C. C. Honeycutt, D. R. Flebbe, S. F. Andrew, S. J. Provost, L. McCormick, A. Van Ry, E. McCarthy, J.-P. M. Todd, S. Bao, I.-T. Teng, S. Marciano, Y. Rudich, C. Li, , D. C. Douek

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

bioRxiv · Jun 9, 2023 · PreprintImmunology

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, , Leung

This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.

bioRxiv · Apr 20, 2021 · PreprintImmunology

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

J. R. Francica, B. J. Flynn, K. E. Foulds, A. T. Noe, A. P. Werner, I. N. Morre, M. Gagne, T. S. Johnston, C. Tucker, R. L. Davis, B. Flach, S. O'Connell, S. F. Andrew, E. Lamb, D. R. Flebbe, , McDermott

This study shows that an AS03-adjuvanted SARS-CoV-2 spike protein vaccine induces strong antibody responses and protects nonhuman primates from viral challenge.

bioRxiv · Mar 2, 2021 · PreprintImmunology

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

A. Patel, J. Walters, E. L. Reuschel, K. Schultheis, E. Parzych, E. N. Gary, I. Maricic, M. Purwar, Z. Eblimit, S. N. Walker, D. Guimet, P. Bhojnagarwala, A. Doan, Z. Xu, D. Elwood, , K. E. Broderick

This study evaluates an intradermal DNA vaccine against SARS-CoV-2 in rhesus macaques, showing it induces immune responses and provides protection against viral challenge.

bioRxiv · Jul 28, 2020 · PreprintImmunology